Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

Study Identifier
191622-104
CT.gov Identifier
NCT01224015
EudraCT Identifier
2010-021271-83
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Facial Aesthetics - Fillers
  • Facial Aesthetics - Toxins
    • Study Drug
  • normal saline
  • onabotulinumtoxinA 44 U
  • onabotulinumtoxinA 24 U
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Successfully completed Study 191622-099
    Exclusion Criteria:
    * Known immunization or hypersensitivity to botulinum toxin of any serotype * Anticipated need for treatment with botulinum toxin of any serotype during the study (except for study treatment) * Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral sclerosis * Anticipated need for surgery or hospitalization during the study

    Protocol Summary

    This study will evaluate the safety and efficacy of botulinum toxin type A compared to placebo for the treatment of Crow's Feet Lines and Frown Lines (Facial Rhytides) for patients who successfully completed Study 191622-099.

    Study Locations

    Location
    Status
    Location
    Newport Beach, California, United States
    Status
    Not applicable
    Location
    Vancouver, British Columbia, Canada
    Status
    Not applicable
    Location
    Antibes, France
    Status
    Not applicable
    Location
    Berlin, Germany
    Status
    Not applicable